Oblato, Inc. announced that it will issue 15,000,000 common shares at an issue price for gross proceeds of KRW 18,408,000,000 on February 6, 2023. The transaction will include participation from HLB Therapeutics Co.,Ltd. The transaction has been approved by the board of directors of the company. The company is expected to close the transaction on February 14, 2023.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
9,340 KRW | -5.56% | -11.89% | +113.00% |
1st Jan change | Capi. | |
---|---|---|
+113.00% | 538M | |
+20.94% | 72.78B | |
-1.26% | 24.24B | |
+8.07% | 8.59B | |
+8.25% | 8.38B | |
-19.42% | 8.09B | |
+5.56% | 4.81B | |
+16.83% | 4.32B | |
-1.83% | 4.05B | |
+26.97% | 3.79B |
- Stock Market
- Equities
- A115450 Stock
- News HLB Therapeutics Co.,Ltd.
- Oblato, Inc. announced that it expects to receive KRW 18.408 billion in funding from HLB Therapeutics Co.,Ltd.